vs

Side-by-side financial comparison of KEMPER Corp (KMPR) and DENTSPLY SIRONA Inc. (XRAY). Click either name above to swap in a different company.

KEMPER Corp is the larger business by last-quarter revenue ($1.1B vs $961.0M, roughly 1.2× DENTSPLY SIRONA Inc.). KEMPER Corp runs the higher net margin — -0.7% vs -15.2%, a 14.5% gap on every dollar of revenue. On growth, DENTSPLY SIRONA Inc. posted the faster year-over-year revenue change (6.2% vs -4.7%). KEMPER Corp produced more free cash flow last quarter ($166.2M vs $60.0M). Over the past eight quarters, DENTSPLY SIRONA Inc.'s revenue compounded faster (0.4% CAGR vs -0.5%).

Kemper Corporation is an American insurance provider with corporate headquarters located in Chicago, Illinois. With nearly $13 billion in assets, the Kemper family of companies provides insurance to individuals, families, and businesses.

Dentsply Sirona Inc. is an American dental equipment manufacturer and dental consumables producer that markets its products in over 120 countries. It has factories in 21 countries. The present company is largely the result of a merger in 1993 in which Gendex Corporation acquired Dentsply International Inc. for $590 million.

KMPR vs XRAY — Head-to-Head

Bigger by revenue
KMPR
KMPR
1.2× larger
KMPR
$1.1B
$961.0M
XRAY
Growing faster (revenue YoY)
XRAY
XRAY
+10.9% gap
XRAY
6.2%
-4.7%
KMPR
Higher net margin
KMPR
KMPR
14.5% more per $
KMPR
-0.7%
-15.2%
XRAY
More free cash flow
KMPR
KMPR
$106.2M more FCF
KMPR
$166.2M
$60.0M
XRAY
Faster 2-yr revenue CAGR
XRAY
XRAY
Annualised
XRAY
0.4%
-0.5%
KMPR

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
KMPR
KMPR
XRAY
XRAY
Revenue
$1.1B
$961.0M
Net Profit
$-8.0M
$-146.0M
Gross Margin
46.1%
Operating Margin
-14.5%
Net Margin
-0.7%
-15.2%
Revenue YoY
-4.7%
6.2%
Net Profit YoY
-108.2%
66.0%
EPS (diluted)
$-0.03
$-0.74

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
KMPR
KMPR
XRAY
XRAY
Q4 25
$1.1B
$961.0M
Q3 25
$1.2B
$904.0M
Q2 25
$1.2B
$936.0M
Q1 25
$1.2B
$879.0M
Q4 24
$1.2B
$905.0M
Q3 24
$1.2B
$951.0M
Q2 24
$1.1B
$984.0M
Q1 24
$1.1B
$953.0M
Net Profit
KMPR
KMPR
XRAY
XRAY
Q4 25
$-8.0M
$-146.0M
Q3 25
$-21.0M
$-427.0M
Q2 25
$72.6M
$-45.0M
Q1 25
$99.7M
$20.0M
Q4 24
$97.4M
$-430.0M
Q3 24
$73.7M
$-494.0M
Q2 24
$75.4M
$-4.0M
Q1 24
$71.3M
$18.0M
Gross Margin
KMPR
KMPR
XRAY
XRAY
Q4 25
46.1%
Q3 25
48.8%
Q2 25
52.4%
Q1 25
53.0%
Q4 24
49.3%
Q3 24
52.1%
Q2 24
51.9%
Q1 24
53.1%
Operating Margin
KMPR
KMPR
XRAY
XRAY
Q4 25
-14.5%
Q3 25
-24.1%
Q2 25
-13.7%
Q1 25
7.2%
Q4 24
-56.2%
Q3 24
11.2%
-48.6%
Q2 24
10.1%
5.1%
Q1 24
7.6%
4.4%
Net Margin
KMPR
KMPR
XRAY
XRAY
Q4 25
-0.7%
-15.2%
Q3 25
-1.7%
-47.2%
Q2 25
5.9%
-4.8%
Q1 25
8.4%
2.3%
Q4 24
8.2%
-47.5%
Q3 24
6.3%
-51.9%
Q2 24
6.7%
-0.4%
Q1 24
6.2%
1.9%
EPS (diluted)
KMPR
KMPR
XRAY
XRAY
Q4 25
$-0.03
$-0.74
Q3 25
$-0.34
$-2.14
Q2 25
$1.12
$-0.22
Q1 25
$1.54
$0.10
Q4 24
$1.51
$-2.09
Q3 24
$1.14
$-2.46
Q2 24
$1.16
$-0.02
Q1 24
$1.10
$0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
KMPR
KMPR
XRAY
XRAY
Cash + ST InvestmentsLiquidity on hand
$326.0M
Total DebtLower is stronger
$943.5M
$2.3B
Stockholders' EquityBook value
$2.7B
$1.3B
Total Assets
$12.5B
$5.4B
Debt / EquityLower = less leverage
0.35×
1.70×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
KMPR
KMPR
XRAY
XRAY
Q4 25
$326.0M
Q3 25
$371.2M
$363.0M
Q2 25
$407.6M
$359.0M
Q1 25
$545.3M
$398.0M
Q4 24
$1.0B
$272.0M
Q3 24
$696.9M
$296.0M
Q2 24
$539.1M
$279.0M
Q1 24
$520.7M
$291.0M
Total Debt
KMPR
KMPR
XRAY
XRAY
Q4 25
$943.5M
$2.3B
Q3 25
$943.1M
Q2 25
$942.6M
Q1 25
$942.1M
Q4 24
$1.4B
$1.7B
Q3 24
$1.4B
Q2 24
$1.4B
Q1 24
$1.4B
Stockholders' Equity
KMPR
KMPR
XRAY
XRAY
Q4 25
$2.7B
$1.3B
Q3 25
$2.7B
$1.5B
Q2 25
$370.0M
$2.0B
Q1 25
$366.0M
$2.0B
Q4 24
$2.8B
$1.9B
Q3 24
$2.8B
$2.5B
Q2 24
$358.0M
$3.1B
Q1 24
$2.6B
$3.3B
Total Assets
KMPR
KMPR
XRAY
XRAY
Q4 25
$12.5B
$5.4B
Q3 25
$12.4B
$5.7B
Q2 25
$12.6B
$6.1B
Q1 25
$12.5B
$6.0B
Q4 24
$12.6B
$5.8B
Q3 24
$12.6B
$6.6B
Q2 24
$12.6B
$6.9B
Q1 24
$12.6B
$7.1B
Debt / Equity
KMPR
KMPR
XRAY
XRAY
Q4 25
0.35×
1.70×
Q3 25
0.35×
Q2 25
2.55×
Q1 25
2.57×
Q4 24
0.50×
0.90×
Q3 24
0.50×
Q2 24
3.88×
Q1 24
0.54×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
KMPR
KMPR
XRAY
XRAY
Operating Cash FlowLast quarter
$175.0M
$101.0M
Free Cash FlowOCF − Capex
$166.2M
$60.0M
FCF MarginFCF / Revenue
14.7%
6.2%
Capex IntensityCapex / Revenue
0.8%
4.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$553.9M
$104.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
KMPR
KMPR
XRAY
XRAY
Q4 25
$175.0M
$101.0M
Q3 25
$139.9M
$79.0M
Q2 25
$89.6M
$48.0M
Q1 25
$180.0M
$7.0M
Q4 24
$175.1M
$87.0M
Q3 24
$141.9M
$141.0M
Q2 24
$22.9M
$208.0M
Q1 24
$43.0M
$25.0M
Free Cash Flow
KMPR
KMPR
XRAY
XRAY
Q4 25
$166.2M
$60.0M
Q3 25
$133.4M
$40.0M
Q2 25
$82.0M
$16.0M
Q1 25
$172.3M
$-12.0M
Q4 24
$165.4M
$36.0M
Q3 24
$131.4M
$98.0M
Q2 24
$5.2M
$156.0M
Q1 24
$27.7M
$-9.0M
FCF Margin
KMPR
KMPR
XRAY
XRAY
Q4 25
14.7%
6.2%
Q3 25
10.8%
4.4%
Q2 25
6.7%
1.7%
Q1 25
14.4%
-1.4%
Q4 24
13.9%
4.0%
Q3 24
11.1%
10.3%
Q2 24
0.5%
15.9%
Q1 24
2.4%
-0.9%
Capex Intensity
KMPR
KMPR
XRAY
XRAY
Q4 25
0.8%
4.3%
Q3 25
0.5%
4.3%
Q2 25
0.6%
3.4%
Q1 25
0.6%
2.2%
Q4 24
0.8%
5.6%
Q3 24
0.9%
4.5%
Q2 24
1.6%
5.3%
Q1 24
1.3%
3.6%
Cash Conversion
KMPR
KMPR
XRAY
XRAY
Q4 25
Q3 25
Q2 25
1.23×
Q1 25
1.81×
0.35×
Q4 24
1.80×
Q3 24
1.93×
Q2 24
0.30×
Q1 24
0.60×
1.39×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

KMPR
KMPR

Specialty Property Casualty Insurance Segment$995.1M88%
Life Insurance Segment1$140.7M12%

XRAY
XRAY

Essential Dental Solutions$372.0M39%
Equipment And Instruments$160.0M17%
Implants And Prosthetics$150.0M16%
CADCAM$139.0M14%
Wellspect Healthcare$88.0M9%
Orthodontics$52.0M5%

Related Comparisons